Share-based Payment Arrangement, Expense in USD of Eiger BioPharmaceuticals, Inc. from 2012 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Eiger BioPharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from 2012 to Q4 2023.
  • Eiger BioPharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2023 was $683,000, a 63% decline year-over-year.
  • Eiger BioPharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2023 was $5,008,000, a 40% decline year-over-year.
  • Eiger BioPharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5,008,000, a 40% decline from 2022.
  • Eiger BioPharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $8,317,000, a 5.3% increase from 2021.
  • Eiger BioPharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $7,901,000, a 32% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Eiger BioPharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2023 $5,008,000 $683,000 -$1,157,000 -63% 01 Oct 2023 31 Dec 2023 10-K 08 Apr 2024 2023 FY
Q3 2023 $6,165,000 $1,038,000 -$1,184,000 -53% 01 Jul 2023 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $7,349,000 $745,000 -$1,463,000 -66% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q1 2023 $8,812,000 $2,542,000 +$495,000 +24% 01 Jan 2023 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $8,317,000 $1,840,000 -$124,000 -6.3% 01 Oct 2022 31 Dec 2022 10-K 08 Apr 2024 2023 FY
Q3 2022 $8,441,000 $2,222,000 -$108,000 -4.6% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $8,549,000 $2,208,000 +$150,000 +7.3% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $8,399,000 $2,047,000 +$498,000 +32% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $7,901,000 $1,964,000 +$527,000 +37% 01 Oct 2021 31 Dec 2021 10-K 17 Mar 2023 2022 FY
Q3 2021 $7,374,000 $2,330,000 +$885,000 +61% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $6,489,000 $2,058,000 +$596,000 +41% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $5,893,000 $1,549,000 -$80,000 -4.9% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022 2022 Q1
Q4 2020 $5,973,000 $1,437,000 +$89,000 +6.6% 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2023 2022 FY
Q3 2020 $5,884,000 $1,445,000 -$204,000 -12% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $6,088,000 $1,462,000 -$25,000 -1.7% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $6,113,000 $1,629,000 +$434,000 +36% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $5,679,000 $1,348,000 -$163,000 -11% 01 Oct 2019 31 Dec 2019 10-K 10 Mar 2022 2021 FY
Q3 2019 $5,842,000 $1,649,000 +$477,000 +41% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $5,365,000 $1,487,000 +$166,000 +13% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $5,199,000 $1,195,000 +$192,000 +19% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $5,007,000 $1,511,000 +$491,000 +48% 01 Oct 2018 31 Dec 2018 10-K 09 Mar 2021 2020 FY
Q3 2018 $4,516,000 $1,172,000 +$219,000 +23% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $4,297,000 $1,321,000 +$375,000 +40% 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $3,922,000 $1,003,000 -$321,000 -24% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $4,243,000 $1,020,000 -$418,000 -29% 01 Oct 2017 31 Dec 2017 10-K 13 Mar 2020 2019 FY
Q3 2017 $4,661,000 $953,000 -$287,000 -23% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018 2018 Q3
Q2 2017 $4,948,000 $946,000 +$772,000 +444% 01 Apr 2017 30 Jun 2017 10-Q 10 Aug 2018 2018 Q2
Q1 2017 $4,176,000 $1,324,000 +$986,000 +292% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018 2018 Q1
Q4 2016 $3,190,000 $1,438,000 +$1,283,000 +828% 01 Oct 2016 31 Dec 2016 10-K 14 Mar 2019 2018 FY
Q3 2016 $1,907,000 $1,240,000 +$1,218,000 +5536% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017 2017 Q3
Q2 2016 $689,000 $174,000 +$127,000 +270% 01 Apr 2016 30 Jun 2016 10-Q 11 Aug 2017 2017 Q2
Q1 2016 $562,000 $338,000 +$335,000 +11167% 01 Jan 2016 31 Mar 2016 10-Q 12 May 2017 2017 Q1
Q4 2015 $227,000 $155,000 +$2,306,000 01 Oct 2015 31 Dec 2015 10-K 09 Mar 2018 2017 FY
Q3 2015 $2,079,000 $22,000 -$889,000 -98% 01 Jul 2015 30 Sep 2015 10-Q 08 Nov 2016 2016 Q3
Q2 2015 $1,190,000 $47,000 -$701,000 -94% 01 Apr 2015 30 Jun 2015 10-Q 10 Aug 2016 2016 Q2
Q1 2015 $489,000 $3,000 -$516,000 -99% 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016 2016 Q1
Q4 2014 $27,000 $2,151,000 -$1,133,685 -111% 01 Oct 2014 31 Dec 2014 10-K 23 Mar 2017 2016 FY
Q3 2014 $1,160,685 $911,000 +$99,000 +12% 01 Jul 2014 30 Sep 2014 10-Q 12 Nov 2014 2014 Q3
Q2 2014 $1,061,685 $748,000 +$561,000 +300% 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2015 2015 Q2
Q1 2014 $500,685 $519,000 +$440,000 +557% 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015 2015 Q1
Q4 2013 $60,685 $1,017,315 01 Oct 2013 31 Dec 2013 8-K/A 17 Jun 2016
Q3 2013 $812,000 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014 2014 Q3
Q2 2013 $187,000 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $79,000 01 Jan 2013 31 Mar 2013 10-Q 13 May 2014 2014 Q1

Eiger BioPharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $5,008,000 -$3,309,000 -40% 01 Jan 2023 31 Dec 2023 10-K 08 Apr 2024 2023 FY
2022 $8,317,000 +$416,000 +5.3% 01 Jan 2022 31 Dec 2022 10-K 08 Apr 2024 2023 FY
2021 $7,901,000 +$1,928,000 +32% 01 Jan 2021 31 Dec 2021 10-K 17 Mar 2023 2022 FY
2020 $5,973,000 +$294,000 +5.2% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2023 2022 FY
2019 $5,679,000 +$672,000 +13% 01 Jan 2019 31 Dec 2019 10-K 10 Mar 2022 2021 FY
2018 $5,007,000 +$764,000 +18% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2021 2020 FY
2017 $4,243,000 +$1,053,000 +33% 01 Jan 2017 31 Dec 2017 10-K 13 Mar 2020 2019 FY
2016 $3,190,000 +$2,963,000 +1305% 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2019 2018 FY
2015 $227,000 +$200,000 +741% 01 Jan 2015 31 Dec 2015 10-K 09 Mar 2018 2017 FY
2014 $27,000 -$33,685 -56% 01 Jan 2014 31 Dec 2014 10-K 23 Mar 2017 2016 FY
2013 $60,685 -$237,315 -80% 01 Jan 2013 31 Dec 2013 8-K/A 17 Jun 2016
2012 $298,000 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.